Back to results
US 9,469,616 B2Granted
Cyclic compounds and methods of making and using the same
AssigneesCellceutix Corporation, University of Massachusetts
InventorsYan Li, Hitesh Thaker, Gregory N. Tew, Dahui Liu, Wenxi Pan, Richard W Scott, Xiaodong Fan
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin/low molecular weight heparin derivative.
Claims19
A compound of the formula
- wherein:
- X is
- R2 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —C≡C—(CH2)2NH2, —C≡C—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
- R3 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —C≡C—(CH2)2NH2, —C≡C—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
- R4 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —C≡C—(CH2)2NH2, —C≡C—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
- R5 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —C≡C—(CH2)2NH2, —C≡C—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
- R6 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —C≡C—(CH2)2NH2, —C≡C—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
- and
- R7 is H, —NH(CH2)nNH2, —NH(CH2)nNC(═N)NH2, —(CH2)nNH2, —O—(CH2)nNH2, —(CH2)nNC(═N)NH2, —O—(CH2)nNC(═N)NH2, —CH═CH—CH2NH2, —CH═CH—CH2NC(═N)NH2, —CH═CH—(CH2)2NH2, —CH═CH—(CH2)2NC(═N)NH2, —C≡C—CH2NH2, —C≡C—(CH2)2NH2, —C≡C—CH2NC(═N)NH2, or —C≡C—(CH2)2—NC(═N)NH2, where n is 2, 3, or 4;
- or a pharmaceutically acceptable salt thereof.
7 more elements
Dependencies are inferred from the claim text.